| Literature DB >> 35158875 |
Richard Huan Xu1,2, Dong Dong2,3.
Abstract
Objective: To assess the difference between lymphoma survivors' self- and proxy-reported health-related quality of life (HRQoL) and its association with socioeconomic and health statuses.Entities:
Keywords: health-related quality of life; lymphoma; patient–proxy agreement
Year: 2022 PMID: 35158875 PMCID: PMC8833321 DOI: 10.3390/cancers14030607
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Respondent’s characteristics.
| Before PSM ( | After PSM ( | ||||||
|---|---|---|---|---|---|---|---|
| Patient | Proxy | Overall | Patient | Proxy | |||
|
| 1.37 (1–35) | 1.37 (1–30) | 0.99 | 1.34 (1–35) | 1.38 (1–35) | 1.31 (1–13) | 0.99 |
|
| |||||||
| Male | 1077 (51) | 1373 (59.96) | <0.001 | 1421 (60.3) | 708 (60.3) | 713 (60.3) | 0.88 |
| Female | 1033 (49) | 917 (40.04) | 929 (39.7) | 467 (39.7) | 462 (39.7) | ||
|
| |||||||
| 18–40 | 1146 (54.3) | 459 (20) | <0.001 | 919 (39.1) | 460 (39.1) | 459 (39.1) | 0.99 |
| 41–60 | 810 (38.4) | 1024 (44.7) | 1143 (48.6) | 571 (48.6) | 572 (48.6) | ||
| ≥61 | 154 (7.3) | 807 (35.2) | 288 (12.3) | 144 (12.3) | 144 (12.3) | ||
|
| |||||||
| Secondary or below | 772 (36.6) | 1646 (71.9) | <0.001 | 1173 (49.9) | 587 (50) | 586 (49.9) | 0.98 |
| Tertiary or above | 1338 (63.4) | 644 (28.1) | 1177 (50.1) | 588 (50) | 589 (50.1) | ||
|
| |||||||
| HL | 426 (20.2) | 218 (9.5) | <0.001 | 335 (14.3) | 162 (13.8) | 173 (14.7) | 0.81 |
| A-NHL | 977 (40) | 1467 (60) | 1263 (53.7) | 634 (54) | 629 (53.5) | ||
| I-NHL | 707 (53.9) | 605 (46.1) | 752 (32) | 379 (32.2) | 373 (31.7) | ||
|
| |||||||
| Urban resident | 1502 (71.1) | 1430 (62.4) | <0.001 | 1711 (72.9) | 853 (73.1) | 858 (72.7) | 0.84 |
| Rural resident | 597 (28.3) | 854 (37.3) | 636 (27.1) | 320 (26.9) | 316 (27.3) | ||
|
| |||||||
| Single | 340 (16.1) | 131 (5.7) | <0.001 | 245 (10.4) | 79 (6.7) | 50 (4.3) | 0.06 |
| Married | 1605 (76.1) | 2014 (87.9) | 1976 (84.1) | 980 (83.4) | 996 (84.7) | ||
| Divorce/widow(er) | 165 (7.8) | 145 (6.3) | 129 (5.5) | 116 (9.9) | 129 (11) | ||
|
| |||||||
| ≤50,000 RMB | 696 (44.1) | 813 (45.3) | 0.55 | 540 (36.2) | 294 (39.4) | 246 (33.1) | 0.02 |
| 50,001~100,000 RMB | 637 (40.4) | 724 (40.4) | 319 (21.4) | 142 (19) | 177 (23.8) | ||
| ≥100,001 RMB | 245 (15.5) | 256 (14.3) | 631 (42.3) | 310 (41.6) | 321 (43.1) | ||
|
| |||||||
| Employed | 1055 (50) | 837 (36.6) | <0.001 | 1117 (47.5) | 612 (52.1) | 505 (43) | <0.001 |
| Non-employed | 764 (36.2) | 696 (30.4) | 735 (31.3) | 341 (29) | 394 (33.5) | ||
| Retired | 291 (13.8) | 757 (33) | 298 (21.2) | 222 (18.9) | 272 (23.5) | ||
|
| |||||||
| UEBS | 1137 (63.2) | 957 (47.7) | <0.001 | 1175 (59.2) | 629 (63.9) | 546 (54.5) | <0.001 |
| URBS | 214 (11.9) | 341 (17) | 294 (14.8) | 117 (11.9) | 177 (17.7) | ||
| NRMS | 317 (17.6) | 610 (30.3) | 364 (18.3) | 159 (16.2) | 205 (20.5) | ||
| FMS | 130 (7.2) | 102 (5.1) | 153 (7.7) | 79 (8) | 74 (7.4) | ||
|
| 1833 (92.2) | 2002 (91.5) | 0.4 | 2038 (91.6) | 1017 (91.7) | 1021 (91.4) | 0.8 |
|
| 776 (36.8) | 858 (37.5) | 0.9 | 893 (40.1) | 449 (39.7) | 444 (40.5) | 0.72 |
|
| 498 (23.6) | 361 (15.8) | <0.001 | 476 (21.4) | 244 (22) | 232 (20.8) | 0.48 |
|
| 296 (14) | 319 (13.9) | 0.77 | 338 (15.2) | 161 (14.5) | 177 (15.8) | 0.38 |
|
| |||||||
| Never treated | 122 (5.8) | 102 (4.5) | <0.001 | 124 (5.3) | 58 (4.9) | 66 (5.6) | <0.001 |
| Treatment not started yet | 154 (7.3) | 112 (4.9) | 150 (6.4) | 57 (4.9) | 93 (7.9) | ||
| Being treated | 887 (42) | 1281 (55.9) | 1146 (48.8) | 640 (54.5) | 506 (43.1) | ||
| Treatment completed | 947 (44.9) | 795 (34.7) | 930 (39.6) | 420 (35.7) | 510 (43.4) | ||
UEBS: Urban Employee Basic Medical Scheme. URBS: Urban Resident Basic Medical Scheme. NRMS: The New Rural Cooperative Medical Scheme. FMS: Free Medical Scheme. HL: Hodgkin’s lymphoma. A-NHL: Aggressive Non-Hodgkin’s lymphomas. I-NHL: Indolent Non-Hodgkin’s lymphomas.
Patients’ QoL measured by QLQ-C30 and stratified by response type.
| Mean (Standard Deviation) | |||||||
|---|---|---|---|---|---|---|---|
| Type of Response | Type of Caregiver | ||||||
| Self- | Proxy- | Children | Spouse | Others | |||
|
| 1175 | 1175 | 411 (35) | 529 (45) | 235 (20) | ||
|
| 61.85 (22.67) | 60.48 (23) | 0.14 | 62.35 (20.44) | 61.17 (23.02) | 62.52 (25.46) | 0.93 |
|
| |||||||
| Physical | 80.5 (17.56) | 74.08 (22.3) | <0.001 | 75.16 (20.58) | 72.42 (23.61) | 74.52 (24.19) | 0.11 |
| Role | 74.23 (26.97) | 69.33 (30.52) | <0.001 | 69.55 (31.03) | 68.65 (30.25) | 70.5 (30.3) | 0.81 |
| Emotional | 67.28 (23.26) | 63.43 (24.94) | <0.001 | 63.3 (24.28) | 62.85 (25.37) | 64.72 (25.7) | 0.39 |
| Cognitive | 75.42 (20.25) | 77.28 (21.63) | 0.03 | 76.84 (21.94) | 76.64 (21.09) | 79.36 (22.24) | 0.16 |
| Social | 49.63 (30.75) | 51.51 (31.32) | 0.24 | 55.03 (30.58) | 49.02 (31.02) | 49.15 (32.71) | 0.003 |
|
| |||||||
| Fatigue | 41.03 (23.12) | 46.66 (24.58) | <0.001 | 46.9 (24.5) | 47.64 (24.1) | 44.02 (25.69) | 0.24 |
| Nausea/Vomiting | 10.24 (17.82) | 13.9 (22.18) | <0.001 | 12.45 (20.16) | 14.18 (22.28) | 15.82 (25.07) | 0.06 |
| Pain | 19.67 (20.89) | 23.25 (24.16) | <0.001 | 25.02 (24.7) | 21.99 (22.95) | 22.98 (25.72) | 0.18 |
|
| |||||||
| Dyspnea | 38.64 (23.85) | 43.8 (26.05) | <0.001 | 44.28 (25.64) | 45.12 (26.47) | 40 (25.56) | 0.09 |
| Insomnia | 30.27 (28.06) | 30.35 (29.85) | 0.94 | 35.36 (31.81) | 28.42 (28.37) | 25.96 (28.45) | <0.001 |
| Appetite Loss | 20.6 (24.56) | 27.89 (28.17) | <0.001 | 28.71 (27.7) | 26.84 (27.41) | 28.79 (30.63) | 0.85 |
| Constipation | 15.57 (23.68) | 19.23 (26.01) | <0.001 | 21.41 (27.37) | 17.64 (24.44) | 19.01 (26.83) | 0.04 |
| Diarrhea | 12.91 (19.77) | 12.79 (21.09) | 0.89 | 11.35 (19.08) | 13.42 (21.67) | 13.9 (22.97) | 0.11 |
Figure 1Significant difference of QLQ-C30 items, stratified by response type and lymphoma types. Dark and light grey indicates proxy-reported and self-reported patients, respectively; HL: Hodgkin’s lymphoma, A-NHL: Aggressive Non-Hodgkin’s lymphoma, I-NHL: Indolent Non-Hodgkin’s lymphoma.
Relationship between HRQoL and responded type adjusted by socioeconomic characteristics and health status.
| Coefficient (95% Confidence Interval) | |||||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
| Proxy-reported patients | 4.73 (2.36, 7.1) *** | 2.25 (−1.12, 5.61) | 1.46 (−1.39, 4.32) | −3.98 (−6.53, −1.42) ** | −5.09 (−8.62, −1.55) ** |
| Female | −3.72 (−6.06, −1.38) ** | −0.07 (−3.4, 3.25) | −2.28 (−5.1, 0.54) | −3.86 (−6.38, −1.33) ** | 0.06 (−3.43, 3.55) |
| 41–60 | −3.58 (−6.36, −0.79) * | −4.47 (−8.42, −0.52) * | −2.13 (−5.49, 1.22) | −2.65 (−5.65, 0.36) | −6.17 (−10.32, −2.02) ** |
| ≥61 | −8.59 (−14.11, −3.07) ** | −4.13 (−11.95, 3.7) | 3.15 (−3.49, 9.8) | 0.48 (−5.46, 6.43) | 1.77 (−6.45, 9.99) |
| Tertiary and above | −2.44 (−5.17, 0.29) | −3.29 (−7.16, 0.58) | −1.11 (−4.39, 2.17) | −2.42 (−5.36, 0.52) | −3.61 (−7.67, 0.45) |
| Rural resident | −0.41 (−3.71, 2.89) | −4.18 (−8.86, 0.5) | 0.54 (−3.44, 4.51) | 2.25 (−1.3, 5.81) | −1.65 (−6.57, 3.26) |
| Married | 0.97 (−4.11, 6.04) | 3.34 (−3.86, 10.54) | −3.22 (−9.33, 2.89) | 1.5 (−3.97, 6.97) | 2.21 (−5.36, 9.77) |
| Divorce/widow(er) | 3.54 (−2.8, 9.89) | 7.98 (−1.02, 16.98) | 0 (−7.64, 7.63) | 3.33 (−3.51, 10.16) | 1.08 (−8.37, 10.54) |
| 50,001~100,000 | 5.72 (2.46, 8.97) *** | 2.27 (−2.34, 6.89) | 6.81 (2.9, 10.73) *** | 5.68 (2.17, 9.19) ** | 11.52 (6.66, 16.37) *** |
| ≥100,001 | 3.45 (0.8, 6.1) * | 1.75 (−2, 5.5) | 2.82 (−0.36, 6.01) | 1.44 (−1.41, 4.29) | 8.22 (4.27, 12.16) *** |
| Non-employed | −4.19 (−6.93, −1.44) ** | −6.93 (−10.82, −3.03) *** | −4.32 (−7.62, −1.01) * | −4.88 (−7.84, −1.93) ** | −5.98 (−10.07, −1.89) ** |
| Retired | 0.57 (−3.49, 4.63) | 3.58 (−2.18, 9.34) | 0.68 (−4.21, 5.57) | −2.97 (−7.34, 1.41) | 1.18 (−4.87, 7.23) |
| URBS | 1.46 (−3.69, 6.61) | 0.98 (−6.32, 8.29) | 3.27 (−2.93, 9.47) | 1.84 (−3.7, 7.39) | 4.36 (−3.31, 12.03) |
| NRCS | 0.85 (−2.61, 4.3) | 3.38 (−1.52, 8.28) | 1.06 (−3.09, 5.22) | −0.73 (−4.45, 2.99) | 0.78 (−4.36, 5.93) |
| FMS | 2.74 (−1.04, 6.52) | 5.15 (−0.21, 10.52) | 2 (−2.55, 6.55) | −0.54 (−4.62, 3.53) | −0.81 (−6.45, 4.82) |
| Duration | 0.09 (−0.64, 0.82) | 0.51 (−0.53, 1.55) | 0.02 (−0.86, 0.9) | −0.06 (−0.85, 0.72) | 0.39 (−0.7, 1.48) |
| Chemotherapy, Yes | −2.66 (−7.19, 1.87) | −6.35 (−12.78, 0.08) | −4.18 (−9.63, 1.28) | −4.17 (−9.05, 0.72) | −6.52 (−13.27, 0.24) |
| Immunotherapy, Yes | 1.32 (−1.04, 3.67) | 2.12 (−1.21, 5.46) | 0.13 (−2.7, 2.96) | 0.45 (−2.08, 2.99) | 0.37 (−3.13, 3.88) |
| Radiotherapy, Yes | 1.17 (−1.54, 3.88) | 3.75 (−0.09, 7.6) | 0.12 (−3.14, 3.38) | −1.37 (−4.28, 1.55) | 3.11 (−0.92, 7.15) |
| Surgery, Yes | −3.68 (−6.78, −0.59) * | −5.34 (−9.73, −0.95) * | −3.39 (−7.12, 0.33) | −1.81 (−5.15, 1.52) | −5.4 (−10.02, −0.79) * |
| Being treated | −11.42 (−13.72, −9.12) *** | −21.81 (−25.07, −18.54) *** | −12.62 (−15.39, −9.85) *** | −6.98 (−9.46, −4.5) *** | −16.82 (−20.25, −13.39) *** |
Reference group: patient, male, 18–40 years, secondary or below educational level, urban residents, single, family income ≤ 50,000 RMB, active employed, UEBS (Urban Employer Basic Medical Scheme), no chemotherapy, no immunotherapy, no radiotherapy, no surgery, treatment completed. * p < 0.05; ** p < 0.01; *** p < 0.001. URBS = Urban Resident Basic Medical Scheme. NRCS = New Rural Cooperative Medical Scheme. FMS = Free Medical Scheme.